Search results
Showing 1411 to 1425 of 1766 results for patient safety
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
Recommendation ID IPG756/1 Question Evidence on the safety of focal therapy using high-intensity focused ultrasound for localised...
delayed-union and non-union fractures. Further research should include details of patient selection, fracture site, and risk factors and...
procedure against other forms of management. Studies should clearly define patient selection criteria and should report outcomes...
Recommendation ID IPG741/01 Question Evidence on the safety and efficacy of YAG laser vitreolysis for symptomatic vitreous floaters is
Recommendation ID IPG694/1 Question Evidence on the safety and efficacy of permanent His-bundle pacemaker implantation for treating heart
Recommendation ID IPG681/1 Question Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal...
comparative studies against existing forms of management. Studies should record patient selection, joint space measurements in the...
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Name: Consultant: (or affix hospital sticker) Patient decision aid Options for women referred to specialist centres Treating...
Name: Consultant: (or affix hospital sticker) Patient decision aid Options for women referred to specialist centres Treating...
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
including observational data collection. Studies should clearly define patient selection. Outcomes should include completeness of...